Keros Therapeutics, Inc. Treasury Stock Acquired, Average Cost Per Share
Keros Therapeutics, Inc. (KROS) had Treasury Stock Acquired, Average Cost Per Share of $17.75 per share as of 2025-10-15, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Equity › Class of Stock Disclosures
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2026-08-03
- 2025-10-15: Treasury Stock Acquired, Average Cost Per Share $17.75.
| Period end | Treasury Stock Acquired, Average Cost Per Share |
|---|---|
| 2025-10-15 | $17.75 10-Q · filed 2026-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |